Grifols A : Launches a € 400m efficiency plan
>New operational improvement plan - Grifols just announced a plan to improve its efficiency. Under this initiative, the company seeks to reduce its cost base, focusing on three areas: i/ plasma costs, ii/ corporate functions, and iii/ group operational costs. Grifols expects to achieve structural cost savings of c. € 400m p.a. (vs FY 2022 and before the effect of inflation). Most of these measures are expected to be implemented by Q4 2023, however, due to inventory ac...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.